Spots Global Cancer Trial Database for LIPT - Liraglutide in Polycystic Ovary Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: LIPT - Liraglutide in Polycystic Ovary Syndrome
Official Title: A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.
Study ID: NCT02073929
Study Description
Brief Summary: Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Dept. of Medicine and Dept. of Gyn-Obs, Herlev Hospital, Herlev, , Denmark
Herlev Hospital, Dept of Gynecology, Herlev, , Denmark
Dept. of Medicine and Dept. of Obstetrics and Gynaecology, Herlev Hospital, Herlev, , Denmark
Contact Details
Name: Jens Faber, DSc
Affiliation: Dept. of Medicine, Herlev Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
